Clinical trial
Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer
NCT00004182 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00004182 |
|---|---|
| Title | Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer |
| Official title | Phase II Study for the Evaluation of CPT-11 (Irinotecan, Camptosar) in Patients With Metastatic or Recurrent Breast Cancer |
| Lead sponsor | Northwestern University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | irinotecan hydrochloride |
| Start date | Oct 1, 1999 |
| Primary completion | Apr 1, 2000 |
| Completion | Apr 1, 2000 |
| First posted | Aug 20, 2004 |
| Last update posted | Jun 6, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: